PAVmed (PAVM) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 12, 2019
Document And Entity Information
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,061,149
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 6,908,068	$ 8,222,119
Prepaid expenses and other current assets	97,576	238,040
Total current assets	7,005,644	8,460,159
Equipment, net	54,780	36,271
Total assets	7,060,424	8,496,430
Current liabilities
Accounts payable	1,427,056	1,738,837
Accrued expenses and other current liabilities	722,447	1,330,746
Senior Secured Convertible Note at fair value - face value principal of $6,219,000 and $7,750,00 as of June 30, 2019 and December 31, 2018, respectively	6,790,096	7,903,000
Total liabilities	8,939,599	10,972,583
COMMITMENTS AND CONTINGENCIES (NOTE 9)
Stockholders' Equity (Deficit)
Common stock, par value $0.001; 100,000,000 shares authorized, 34,139,220 and 27,142,979 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	34,139	27,143
Additional paid-in capital	40,518,952	32,619,282
Accumulated deficit	(44,251,062)	(36,992,911)
Total PAVmed Inc. Stockholders' Equity (Deficit)	(1,536,448)	(2,314,641)
Noncontrolling interest	(342,727)	(161,512)
Total Stockholders' equity (deficit)	(1,879,175)	(2,476,153)
Total Liabilities and Stockholders' Equity (Deficit)	7,060,424	8,496,430
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred stock	$ 2,161,523	$ 2,031,845

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Face value of principal	$ 6,219,000	$ 775,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	34,139,220	27,142,979
Common stock, shares outstanding	34,139,220	27,142,979
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,113,201	1,069,941
Preferred stock, shares outstanding	1,113,201	1,069,941

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue
General and administrative expense		1,914,154	1,589,974	3,606,865	2,970,458
Research and development expense		1,405,060	1,148,811	2,856,010	1,712,029
Total operating expenses		3,319,214	2,738,785	6,462,875	4,682,487
Loss from operations		(3,319,214)	(2,738,785)	(6,462,875)	(4,682,487)
Other income (expense)
Interest expense - Senior Secured Note			(500,304)		(1,000,608)
Change in fair value - Senior Secured Convertible Note		(161,108)		(720,059)
Debt extinguishment loss - Senior Secured Convertible Note		(258,811)		(259,812)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series A-1 Warrants					(349,796)
Series W Warrants Exchange Offer - April 5, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series W Warrants			(766,456)		(766,456)
Modification - Series Z Warrant Agreement - June 1, 2018			(1,140,995)		(1,140,995)
Change in fair value - Series A Warrants derivative liability					(96,480)
Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability					64,913
Other income (expense), net		(419,919)	(2,407,755)	(979,871)	(3,289,422)
Loss before provision for income tax		(3,739,133)	(5,146,540)	(7,442,746)	(7,971,909)
Provision for income taxes
Net loss - before noncontrolling interest		(3,739,133)	(5,146,540)	(7,442,746)	(7,971,909)
Net loss attributable to noncontrolling interest		145,522	81,200	314,273	81,200
Net loss - attributable to PAVmed Inc.		(3,593,611)	(5,065,340)	(7,128,473)	(7,890,709)
Less: Series B Convertible Preferred Stock dividends		(66,792)	(63,623)	(132,273)	(74,029)
Less: Series A-1 Convertible Preferred Stock dividends					(25,148)
Less: Series A Convertible Preferred Stock dividends	[1]				(26,487)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock					(726,531)
Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock					199,241
Net loss attributable to PAVmed Inc. common stockholders		$ (3,660,403)	$ (5,128,963)	$ (7,260,746)	$ (8,543,663)
Net loss per share - attributable to PAVmed Inc. - basic and diluted		$ (0.13)	$ (0.26)	$ (0.26)	$ (0.44)
Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted		$ (0.13)	$ (0.27)	$ (0.27)	$ (0.48)
Weighted average common shares outstanding - basic and diluted	[2],[3]	27,605,881	19,289,874	27,343,912	17,924,632
[1]	The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to June 30, 2018, and each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. See Note 12, Preferred Stock, for a further discussion of the dividends for each of the respective series of convertible preferred stock.
[2]	Basic weighted-average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
[3]	The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2017			$ 1,032,650	$ 14,551	$ 14,012,053	$ (17,907,611)		$ (2,848,357)
Balance, shares at Dec. 31, 2017	249,667		357,259	14,551,234
Underwritten public offering of common stock, net of offering cost				$ 2,650	4,272,011			4,274,661
Underwritten public offering of common stock, net of offering cost, shares				2,649,818
Equity Subscription Rights Offering, net of offering cost				$ 9,000	9,199,326			9,208,326
Equity Subscription Rights Offering, net of offering cost, shares				9,000,000
Issue common stock - registered offerings, net
Issue common stock - registered offerings, net, shares
Exercise - common stock purchase warrant, net of offering costs
Issue common stock - Senior Secured Convertible Note				$ 309	20,604			20,913
Issue common stock - Senior Secured Convertible Note, shares				308,602
Exchange Offer - March 15, 2018		$ 1,707,244	$ (1,032,650)		1,406,640	(726,531)		1,354,703
Exchange Offer - March 15, 2018, shares	(249,667)	975,568	(357,259)
Exchange Offer - April 5, 2018					766,456			766,456
Series Z Warrant Modification					1,140,995			1,140,995
Exchange Offer - UPOs
Common stock issued - conversion Series B Convertible Preferred Stock
Common stock issued - conversion Series B Convertible Preferred Stock, shares
Series B Convertible Preferred Stock Dividends
Series B Convertible Preferred Stock Dividends, shares
Share subscription receivable							(943)	943
Issue of common stock of majority-owned subsidiary							1,812	1,812
Stock-based compensation					563,266			563,266
Stock-based compensation of majority-owned subsidiary					3,633		8,277	11,910
Net loss						(7,890,709)	(81,200)	(7,971,909)
Balance at Jun. 30, 2018		$ 1,707,244		$ 26,510	31,384,984	26,524,851	72,054	6,521,833
Balance, shares at Jun. 30, 2018		975,568		26,509,654
Balance at Mar. 31, 2018		$ 1,707,244		$ 17,509	19,982,594	(21,459,511)		247,836
Balance, shares at Mar. 31, 2018		975,568		17,509,654
Underwritten public offering of common stock, net of offering cost
Underwritten public offering of common stock, net of offering cost, shares
Equity Subscription Rights Offering, net of offering cost				$ 9,000	9,199,326			9,208,326
Equity Subscription Rights Offering, net of offering cost, shares				9,000,000
Issue common stock - registered offerings, net
Issue common stock - registered offerings, net, shares
Exercise - common stock purchase warrant, net of offering costs
Issue common stock - Senior Secured Convertible Note
Issue common stock - Senior Secured Convertible Note, shares
Exchange Offer - March 15, 2018
Exchange Offer - March 15, 2018, shares
Exchange Offer - April 5, 2018					766,456			766,456
Series Z Warrant Modification					1,140,995			1,140,995
Exchange Offer - UPOs
Common stock issued - conversion Series B Convertible Preferred Stock
Common stock issued - conversion Series B Convertible Preferred Stock, shares
Series B Convertible Preferred Stock Dividends
Series B Convertible Preferred Stock Dividends, shares
Share subscription receivable							(943)	(943)
Issue of common stock of majority-owned subsidiary							1,812	1,812
Stock-based compensation					291,980			291,980
Stock-based compensation of majority-owned subsidiary					3,633		8,277	11,910
Net loss						(5,065,340)	(81,200)	(5,146,540)
Balance at Jun. 30, 2018		$ 1,707,244		$ 26,510	31,384,984	26,524,851	72,054	6,521,833
Balance, shares at Jun. 30, 2018		975,568		26,509,654
Balance at Dec. 31, 2018		$ 2,031,845		$ 27,143	32,619,282	(36,992,911)	(161,512)	(2,476,153)
Balance, shares at Dec. 31, 2018		1,069,941		27,142,979
Underwritten public offering of common stock, net of offering cost
Underwritten public offering of common stock, net of offering cost, shares				5,480,000				5,480,000
Equity Subscription Rights Offering, net of offering cost
Equity Subscription Rights Offering, net of offering cost, shares
Issue common stock - registered offerings, net				$ 5,480	$ 5,373,422			$ 5,378,902
Issue common stock - registered offerings, net, shares				5,480,000
Exercise - common stock purchase warrant, net of offering costs
Issue common stock - Senior Secured Convertible Note				$ 1,516	1,812,257			1,813,773
Issue common stock - Senior Secured Convertible Note, shares				1,516,241
Exchange Offer - March 15, 2018
Exchange Offer - March 15, 2018, shares
Exchange Offer - April 5, 2018
Series Z Warrant Modification
Exchange Offer - UPOs
Common stock issued - conversion Series B Convertible Preferred Stock
Common stock issued - conversion Series B Convertible Preferred Stock, shares
Series B Convertible Preferred Stock Dividends		$ 129,678				$ (129,678)
Series B Convertible Preferred Stock Dividends, shares		43,260
Share subscription receivable
Issue of common stock of majority-owned subsidiary
Stock-based compensation					705,686			705,686
Stock-based compensation of majority-owned subsidiary					8,305		133,058	141,363
Net loss						(7,128,473)	(314,273)	(7,442,746)
Balance at Jun. 30, 2019		$ 2,161,523		$ 34,139	40,518,952	(44,251,062)	(342,727)	(1,879,175)
Balance, shares at Jun. 30, 2019		1,113,201		34,139,220
Balance at Mar. 31, 2019		$ 2,096,041		$ 27,193	33,025,961	(40,591,969)	(225,760)	(5,668,534)
Balance, shares at Mar. 31, 2019		1,091,354		27,193,023
Underwritten public offering of common stock, net of offering cost
Underwritten public offering of common stock, net of offering cost, shares
Equity Subscription Rights Offering, net of offering cost				$ 5,480	5,373,423			5,378,903
Equity Subscription Rights Offering, net of offering cost, shares				5,480,000
Issue common stock - registered offerings, net
Issue common stock - registered offerings, net, shares
Exercise - common stock purchase warrant, net of offering costs
Issue common stock - Senior Secured Convertible Note				$ 1,466	1,759,760			1,761,226
Issue common stock - Senior Secured Convertible Note, shares				1,466,197
Exchange Offer - March 15, 2018
Exchange Offer - March 15, 2018, shares
Exchange Offer - April 5, 2018
Series Z Warrant Modification
Exchange Offer - UPOs
Common stock issued - conversion Series B Convertible Preferred Stock
Common stock issued - conversion Series B Convertible Preferred Stock, shares
Series B Convertible Preferred Stock Dividends	$ 65,482					(65,482)
Series B Convertible Preferred Stock Dividends, shares	21,847
Share subscription receivable
Issue of common stock of majority-owned subsidiary					4,201		28,555	32,756
Stock-based compensation					355,607			355,607
Stock-based compensation of majority-owned subsidiary
Net loss						(3,593,611)	(145,522)	(3,739,133)
Balance at Jun. 30, 2019		$ 2,161,523		$ 34,139	$ 40,518,952	$ (44,251,062)	$ (342,727)	$ (1,879,175)
Balance, shares at Jun. 30, 2019		1,113,201		34,139,220

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss - before noncontrolling interest ("NCI")	$ (3,739,133)	$ (5,146,540)	$ (7,442,746)	$ (7,971,909)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense	3,281	1,802	6,549	3,605
Stock-based compensation	388,363	303,890	847,049	575,176
Change in fair value - Senior Secured Convertible Note	161,108		720,059
Debt extinguishment - Senior Secured Convertible Note	258,811		259,812
Interest expense added to principal of Senior Secured Note				194,570
Interest expense - amortization of debt discount - Senior Secured Note				611,467
Series A and Series A-1 Exchange Offer - March 15, 2018				349,796
Series W Warrants Exchange Offer - April 5, 2018				766,456
Modification expense - Series Z Warrant - June 1, 2018				1,140,995
Change in fair value - Series A Warrants derivative liability				96,480
Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability				(64,913)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			140,464	(1,603)
Accounts payable			(311,781)	432,792
Accrued expenses and other current liabilities			(608,299)	(38,267)
Net cash flows used in operating activities			(6,388,893)	(3,902,149)
Cash flows from investing activities
Purchase of equipment			(25,058)
Net cash flows used in investing activities			(25,058)
Cash flows from financing activities
Proceeds - issue of common stock - registered offerings			5,480,000
Payment - offering costs - registered offerings			(101,098)
Proceeds - issue of common stock in an underwritten public offering				4,388,099
Payment - offering costs - underwritten public offering				(113,438)
Proceeds - issue units - equity subscription rights offering				9,437,000
Payment - offering costs - equity subscription rights offering				(228,674)
Payment - Senior Secured Convertible Note - bi-monthly non-installment payments - cash			(279,002)
Proceeds - issue common stock - majority-owned subsidiary				869
Proceeds - issue of common stock upon exercise of warrants, net				20,913
Net cash flows provided by financing activities			5,099,900	13,504,769
Net (decrease) increase in cash			(1,314,051)	9,602,620
Cash, beginning of period			8,222,119	1,535,022
Cash, end of period	$ 6,908,068	$ 11,137,642	$ 6,908,068	$ 11,137,642

The Company and Description of

The Company and Description of the Business	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Description of the Business	Note 1 — The Company and Description of the Business PAVmed Inc. (“PAVmed” or the “Company”) is a highly-differentiated multi-product technology medical device company organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. Since inception on June 26, 2014, the Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. On May 8, 2018, Lucid Diagnostics Inc., a majority-owned subsidiary of the Company, was incorporated in the State of Delaware, and on May 12, 2018, Lucid Diagnostics Inc. entered into a license agreement with Case Western Reserve University (“CWRU”) with respect to the intellectual property and proprietary technologies referred to as EsoCheck™ and “EsoGuard™”. To date, the Company has not recognized revenue. The ability to generate revenue depends upon the Company’s ability to successfully complete the development, obtain regulatory approval, and to initiate commercialization of its product candidates. Currently, the Company’s activities are focused principally on obtaining FDA clearance and initializing commercialization of the lead product candidates, including CarpX™, EsoGuard™, EsoCheck™, and PortIO™, along with advancing additional product candidates through their respective research and development phase, including DisappEAR™ and NextFlo TM The Company has financed its operations principally through the issuances of its common stock, preferred stock, warrants, and debt, including: proceeds from the April 28, 2016 closing of its IPO and more recently in 2019 from registered offerings of shares of common stock of the Company. Collectively, PAVmed Inc. and Lucid Diagnostics Inc. have proprietary rights to the trademarks used herein, including, among others, PAVmed™, Lucid Diagnostics™, Caldus™, CarpX™, DisappEAR™, EsoCheck™, EsoGuard™, EsoCheck™ Cell Collection Device™, EsoCheck™ CCD™, EsoCheck™ Technology, NextCath™, NextFlo™, PortIO™, and “Innovating at the Speed of Life” ™. Solely as a matter of convenience, trademarks and trade names referred to herein may or may not be accompanied with the requisite marks of “™” or “®”, however, the absence of such marks is not intended to indicate, in any way, either of PAVmed Inc. or Lucid Diagnostics Inc. will not assert, to the fullest extent possible under applicable law, its rights or the rights to such trademarks and trade names.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the minority ownership interest in the Company’s majority-owned subsidiary Lucid Diagnostics Inc. and the corresponding noncontrolling interest. The condensed balance sheet as of December 31, 2018, which has been derived from audited financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and related notes thereto as of and for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC. Going Concern During the six months ended June 30, 2019, the Company incurred a loss attributable to PAVmed common stockholders of $7.3 million, and negative cash flows from operating activities of $6.4 million. As of June 30, 2019, the Company had negative working capital of $1.9 million inclusive of approximately $6.8 million of the estimated fair value of the Senior Secured Convertible Note classified as a current liability and approximately $6.9 million of cash. The Company anticipates incurring operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating losses as it completes the development of its products, seeks regulatory approvals and clearances of such products, and begin to commercially market such products. These factors, which have existed since inception, are expected to continue, and raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued. The Company’s ability to fund its operations is dependent upon management’s plans, which include raising additional capital, refinance the debt upon maturity, obtaining regulatory approvals for its products currently under development, commercializing and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance the Company will be successful in these efforts. The Company’s unaudited condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern Recent Accounting Pronouncements Adoption of new accounting principles In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) Recently issued accounting pronouncements, not yet adopted: In June 2018, the FASB issued its Accounting Standards Update (“ASU”) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07), which, upon the effective date, will result in non-employee stock-based compensation to be within the scope of ASC-718, and will supersede ASC 505-50. A principal change of the new guidance is to eliminate the ASC 505-50 required periodic fair value remeasure (“mark-to-market”) and use of the “contractual term” as an input to the Black-Scholes option pricing model to calculate the estimated fair value of stock options issued to non-employees, in favor of the ASC 718 one-time measurement of the grant date fair value and use of an “expected term” as such valuation input, for non-employee stock-based compensation expense, as is currently done for employee stock-based compensation expense. The amended ASC-718 non-employee stock-based compensation provisions are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within such fiscal year, and for all other companies for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606). With respect to the Company and its majority-owned subsidiary, the amended ASC-718 non-employee stock-based compensation provisions are required to be adopted by no later than January 1, 2020, resulting from the Company’s “JOBS Act EGC Election” as discussed Company’s Annual Report of Form 10-K for the year ended December 31, 2018. Additionally, the Company, under its “JOBS Act EGC Accounting Standards Election”, adopted ASC 606 as of January 1, 2019, which is the required adoption date of ASC 606 for private companies. At this time, the Company and its majority-owned subsidiary continue to apply the guidance of ASC-505-50 with respect to non-employee stock-based compensation, subject-to the future adoption date of the amended ASC-718 provisions with respect to non-employee stock-based compensation. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) - Part I - Accounting for Certain Financial Instruments with Down-Round Features, and Part II - Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Note 3 — Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: June 30, December 31, 2019 2018 Security deposits $ 14,250 $ 14,250 Advanced payments to service providers and suppliers 83,326 223,790 Total prepaid expenses and other current assets $ 97,576 $ 238,040

Equipment, Net

Equipment, Net	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Equipment, Net	Note 4 — Equipment, Net June 30, December 31, 2019 2018 Research and development equipment $ 62,590 $ 40,380 Computer equipment 19,432 16,584 Equipment, gross 82,022 56,964 Less: accumulated depreciation (27,242 ) (20,693 ) Equipment, net $ 54,780 $ 36,271 Depreciation expense recognized was $3,281 and $6,549 for the three and six months ended June 30, 2019, respectively, and $1,802 and $3,605 for the three and six months ended June 30, 2018, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2019
Accrued Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 5 — Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of: June 30, December 31, 2019 2018 Bonus $ 115,400 $ 873,621 Payroll — 145,937 Vacation 102,180 38,763 Employee Stock Purchase Plan 15,381 — License agreement fee 222,553 222,553 Milestone payment 75,000 — Operating expenses 191,933 49,872 Total accrued expenses and other current liabilities $ 722,447 $ 1,330,746 The accrued bonus as of June 30, 2019 represents the estimated amount recognized on a pro rata basis during 2019 of the guaranteed bonus payment to the Company’s Chief Executive Officer (“CEO”) under the CEO Employment Agreement. At December 31, 2018, the accrued bonus represents the guaranteed bonus payment to the CEO and discretionary bonus payments to the CEO and other employees. The accrued payroll at December 31, 2018 represents earned but unpaid salary payable to the Company’s CEO for the period July 1, 2017 to January 31, 2018, under the terms of the previous Senior Secured Note, and was subsequently paid in January 2019. The Employee Stock Purchase Plan (“ESPP”) payable represents employee authorized withheld payroll deductions payable under the PAVmed Inc. ESPP. See Note 9, Stock-Based Compensation The accrued license agreement fee as of June 30, 2019 and December 31, 2018 is the remaining unpaid balance of the license fee incurred in connection with the “CWRU License Agreement”. The accrued milestone payment is with respect to the achievement of a milestone under the “CWRU License Agreement”, as discussed in Note 6, Agreements Related to Acquired Intellectual Property Rights

Agreements Related to Acquired

Agreements Related to Acquired Intellectual Property Rights	6 Months Ended
	Jun. 30, 2019
Intellectual Property Right [Abstract]
Agreements Related to Acquired Intellectual Property Rights	Note 6 — Agreements Related to Acquired Intellectual Property Rights Patent License Agreement - Case Western Reserve University On May 12, 2018, Lucid Diagnostics Inc., a majority-owned subsidiary of the Company, entered into a patent license agreement with Case Western Reserve University (“CWRU”), for the exclusive worldwide license of the intellectual property rights for two distinct proprietary technologies, referred to as “EsoCheck™”, an esophageal cell sample collection device, and EsoGuard™, a panel of methylated DNA biomarkers - the “CWRU License Agreement”. Under the CWRU License Agreement, Lucid Diagnostics Inc. recognized an accrued license fee of approximately $273,000, including an initial payment of $50,000, and subsequent quarterly payments of $50,000 until such fee is paid-in-full, provided, however, the commencement of the quarterly payments is subject to Lucid Diagnostics Inc. consummation of a bona fide financing with an unrelated third-party in excess of $500,000. In this regard, the remaining balance of the CWRU License Agreement is unpaid and has been recognized as an accrued expense liability as of June 30, 2019 and December 31, 2018. The CWRU License Agreement fee was recognized on the May 12, 2018 effective date as a current period research and development expense, with the remaining unpaid balance included in accrued expenses and other current liabilities. The CWRU License Agreement also provides for potential payments upon the achievement of certain product development and regulatory clearance milestones. In this regard, upon FDA approval on June 21, 2019 of the EsoCheck™ device, the Company incurred a $75,000 research and development expense in connection with such milestone. If Lucid Diagnostics Inc. does not meet certain milestones listed in the CWRU License Agreement, then CWRU has the right, in its sole discretion, to require the Company to transfer to CWRU a percentage, varying up to 100%, of the shares of common stock of Lucid Diagnostics Inc. held by the Company. Lucid Diagnostics Inc. will also be required to pay a minimum annual royalty commencing the year after the first commercial sale of products resulting from the commercialization of the licensed intellectual property, with the minimum amount rising based on net sales of such product(s), if any. Such contingent milestone and /or royalty payments, if any, will be recognized in the period in which such payment obligations are incurred. Reimbursement of patent fees under the CWRU License Agreement recognized as research and development expense was $47,186 and $78,148 in three and six months ended June 30, 2019, respectively. There were no such expenses in the corresponding periods of the prior year. Patent License Agreement - Tufts University - Antimicrobial Resorbable Ear Tubes In November 2016, the Company executed a Patent License Agreement (the “Tufts Patent License Agreement”) with Tufts University and its co-owners, the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital (the “Licensors”). Pursuant to the Tufts Patent License Agreement, the Licensors granted the Company the exclusive right and license to certain patents in connection with the development and commercialization of antimicrobial resorbable ear tubes based on a proprietary aqueous silk technology conceived and developed by the Licensors. Reimbursement of patent fees under the Tufts Patent License Agreement recognized as research and development expense was $29,390 and $33,258 in the three and six months ended June 30, 2019, respectively, and $25,876 and $61,713 in the three and six months ended June 30, 2018, respectively. The Tufts Patent License Agreement also provides for potential payments from the Company to the Licensors upon the achievement of certain product development and regulatory clearance milestones as well as royalty payments on net sales upon the commercialization of products developed utilizing the licensed patents. The Company will recognize as a current period expense for contingent milestone payments or royalties in the period in which such payment obligations are incurred, if any.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 — Related Party Transactions Effective October 31, 2018, a management services agreement with HCP/Advisors LLC, an affiliate of a former director of the Company, expired and was not renewed by the Company, and as such, no expense was incurred in the current year period. In the prior year period, the Company previously incurred an expense of $75,000 and $150,000 in the three and six months ended June 30, 2018, with such fees included in “general and administrative expenses”.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 — Commitments and Contingencies The Company’s corporate office lease is on a month-to-month basis, with a 5% per annum increase in the monthly lease payment effective February 1 of each year, and the lease agreement may be cancelled with three months written notice. Total rent expense incurred under the corporate office space lease arrangement was $32,992 and $65,461 for the three and six months ended June 30, 2019, respectively and $31,421 and $62,344 for the three and six months ended June 30, 2018, respectively. In the ordinary course of our business, particularly as we begin commercialization of our products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company does not believe it is currently a party to any other pending legal proceedings. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. We have employment agreements with certain of the Company’s executive officers, which provide for minimum salary and a guaranteed bonus with respect to the employment agreement with the Chief Executive Officer and discretional bonus payments under the respective employment agreements with other executive officers. The employment agreements also provide for potential severance payments under certain events as defined in the respective employment agreements. The contingent severance compensation payment(s) obligations under each respective employment agreement, if any, will be recognized as a current period expense if and when such payment obligation is incurred.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 9 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (“PAVmed Inc. 2014 Equity Plan”), adopted by the Company’s board of directors and stockholders in November 2014, is designed to enable the Company to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire a proprietary interest in the Company. The PAVmed Inc. 2014 Equity Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards, and other stock-based awards subject to limitations under applicable law. All awards under the PAVmed Inc. 2014 Equity Plan are subject to approval by the compensation committee of the Company’s board of directors. Stock options and restricted stock awards are issued and outstanding under the PAVmed Inc. 2014 Equity Plan. A total of 7,951,081 shares of common stock of PAVmed Inc. are reserved for issuance under the PAVmed Inc. 2014 Equity Plan, with 2,648,406 shares available for grant as of June 30, 2019, exclusive of 500,854 PAVmed Inc. stock options previously granted outside the PAVmed Inc. 2014 Equity Plan. PAVmed Inc 2014 Equity Plan - Stock Options Weighted Number Average Aggregate Stock Exercise Intrinsic PAVmed Inc. 2014 Equity Plan - Stock Options Options Price Value Outstanding stock options at December 31, 2018 3,327,140 $ 4.40 Granted 1,825,000 $ 1.00 Exercised — $ — Forfeited (48,611 ) $ 5.00 Outstanding stock options at June 30, 2019 5,103,529 $ 2.71 $ 257,500 Vested and exercisable stock options at June 30, 2019 2,620,019 $ 3.83 $ 43,292 Unvested stock options at June 30, 2019 2,483,510 $ 1.53 $ 214,208 The aggregate intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of June 30, 2019 and December 31, 2018 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. During the six months ended June 30, 2019, an aggregate of 1,825,000 stock options were granted under the PAVmed Inc. 2014 Equity Plan, each with a ten year contractual term from date-of-grant, including: March 2019 - 800,000 stock options granted to non-executive members of the Company’s board of directors and 950,000 stock options granted to employees and an executive member of the Company’s board of directors, with a grant date of March 7, 2019, an exercise price of $1.00 per share of PAVmed Inc. common stock, and vesting ratably on a quarterly basis commencing March 31, 2019 and ending December 31, 2021; and, May 2019 - 25,000 stock options granted to a non-employee consultant, with a grant date of May 21, 2019, an exercise price of $1.10 per share of PAVmed Inc. common stock, and vesting ratably on a quarterly basis commencing June 30, 2019 and ending March 31, 2022; and, June 2019 - 50,000 stock options granted to a new hire employee, with a grant date of June 3, 2019, an exercise price of $1.08 per share of PAVmed Inc. common stock, and vesting ratably on a quarterly basis commencing June 30, 2019 and ending March 31, 2022. In April 2019, 48,611 stock options previously granted under the PAVmed Inc. 2014 Equity Plan were forfeited upon expiring unexercised. As of June 30, 2019, the weighted average remaining contractual term of outstanding stock options was 8.6 years for stock options outstanding and 7.8 years for stock options vested and exercisable, under the PAVmed Inc. 2014 Equity Plan. PAVmed Inc 2014 Equity Plan - Restricted Stock Awards On March 15, 2019, a total of 700,000 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, representing a corresponding number of shares of common stock of the Company, which vest ratably on an annual basis commencing March 15, 2020 and ending March 15, 2022. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. As of June 30, 2019, no restricted stock awards had vested. PAVmed Inc Employee Stock Purchase Plan The PAVmed Inc. Employee Stock Purchase Plan (“ESPP”), adopted by the Company’s board of directors effective April 1, 2019, with a reservation of 250,000 shares of PAVmed Inc. common stock, provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the “purchase price per share” is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are April 1 and October 1, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019 with a corresponding share purchase date of October 1, 2019. The payroll deductions are included in accrued expense and other current liabilities, as discussed in Note 4, Accrued Expense and Other Current Liabilities Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (the “Lucid Diagnostics Inc. 2018 Equity Plan”) became effective on May 12, 2018 and is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed above. The Lucid Diagnostics Inc. 2018 Equity Plan is designed to enable Lucid Diagnostics Inc. to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of Lucid Diagnostics Inc. The Lucid Diagnostics Inc. 2018 Equity Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics Inc. board of directors. Stock options are issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan. A total of 2,000,000 shares of common stock of Lucid Diagnostics Inc. are reserved for issuance under the Lucid Diagnostics Inc. 2018 Equity Plan, with 1,525,000 shares available for grant as of June 30, 2019, exclusive of 300,000 Lucid Diagnostics Inc. stock options previously granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. Lucid Diagnostics Inc 2018 Equity Plan - Stock Options Weighted Number Average Stock Exercise Lucid Diagnostics Inc. 2018 Equity Plan - Stock Options Options Price Outstanding stock options at December 31, 2018 375,000 $ 0.60 Granted 400,000 $ 1.00 Exercised — $ — Forfeited — $ Outstanding stock options at June 30, 2019 775,000 $ 0.81 Vested and exercisable stock options at June 30, 2019 374,999 $ 0.83 Unvested stock options at June 30, 2019 400,001 $ 0.78 During the six months ended June 30, 2019, an aggregate of 400,000 Lucid Diagnostics Inc. stock options were granted under the Lucid Diagnostics Inc. 2018 Equity Plan, each having a ten year contractual term from date-of-grant, including: 300,000 stock options granted to an employee of PAVmed Inc., with a grant date of February 18, 2019, an exercise price of $1.00 per share of common stock of Lucid Diagnostics Inc., with 200,000 such stock options vesting immediately upon grant, and 100,000 of such stock options vesting ratably on a quarterly basis commencing March 31, 2019 and ending December 31, 2021; and, 100,000 stock options granted to an employee of PAVmed Inc., with a grant date of June 3, 2019, an exercise price of $1.00 per share of common stock of Lucid Diagnostics Inc., vesting ratably on a quarterly basis commencing June 30, 2019 and ending March 31, 2022. As of June 30, 2019, the weighted average remaining contractual term was 9.3 years for stock options outstanding and 9.3 years for stock options vested and exercisable, under the Lucid Diagnostics Inc. 2018 Equity Plan. Stock-Based Compensation Expense Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards, for the periods indicated, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 General and administrative expenses $ 299,346 $ 233,962 $ 584,009 $ 453,356 Research and development expenses 89,017 69,928 263,040 121,820 Total $ 388,363 $ 303,890 $ 847,049 $ 575,176 The stock-based compensation expense related to stock options granted to employees and directors is based on the grant-date estimated fair value, and for stock options granted to non-employees is based on the vesting date estimated fair value, with the expense recognized on a straight-line basis over the award’s requisite service period, which is generally the vesting period. The consolidated research and development stock-based compensation expense presented above includes expense recognized by Lucid Diagnostics Inc. of $4,202 and $8,305 in the three and six months ended June 30, 2019, respectively, and $3,633 in the three and six months ended June 30, 2018, with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees providing services to Lucid Diagnostics Inc., and $28,555 and $133,058 in the three and six months ended June 30, 2019 and $8,277 in the three and six months ended June 30, 2018, with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to PAVmed Inc. employees and to non-employees, each providing services to Lucid Diagnostics Inc. As of June 30, 2019, with respect to PAVmed Inc. stock options, total unrecognized stock-based compensation expense of approximately $1.7 million is expected to be recognized over the weighted average remaining requisite service period of 1.5 years; and, with respect to PAVmed Inc. restricted stock awards, total unrecognized stock-based compensation expense of approximately $0.7 million is expected to be recognized over the weighted average remaining requisite service period of 2.7 years. As of June 30, 2019, with respect to Lucid Diagnostics Inc. stock options, total unrecognized stock-based compensation expense of approximately $0.2 million is expected to be recognized over the weighted average remaining requisite service period of 2.2 years. Stock-based compensation expense recognized for PAVmed Inc. stock options granted to employees and members of the board of directors was based on a weighted average estimated fair value of $0.93 and $1.23 per share of PAVmed Inc. common stock, during the six months ended June 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 2018 Risk free interest rate 2.3 % 2.0 % Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 50 % 50 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized for PAVmed Inc. stock options granted to non-employees was based on a weighted average estimated fair value of $1.90 and $1.96 per share of PAVmed Inc. common stock, during the six months ended June 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 2018 Risk free interest rate 2.3 % 2.6 % Expected term of stock options (in years) 8.7 9.0 Expected stock price volatility 60 % 60 % Expected dividend yield 0 % 0 % The PAVmed Inc. restricted stock awards granted to employees were measured at their grant date estimated fair value based on the date-of-grant quoted price per share of PAVmed Inc. common stock. The 700,000 restricted stock awards granted on March 15, 2019 had an aggregate fair value of $742,000, recognized ratably over the requisite service period, which is the vesting period, commencing on the March 15, 2019 grant date and ending on the March 15, 2022 final vesting date. In this regard, the stock-based compensation expense recognized for such restricted stock awards in the three and six months ended June 30, 2019 was $61,833 and $82,444, respectively. Stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to employees during the three and six months ended June 30, 2019 was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 Risk free interest rate 2.3 % Expected term of stock options (in years) 5.8 Expected stock price volatility 63 % Expected dividend yield 0 % There was no stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to employees in the corresponding prior year period. Stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to non-employees during the six months ended June 30, 2019 and 2018 was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, June 30, 2019 2018 Risk free interest rate 2.2 % 2.9 % Expected term of stock options (in years) 9.1 9.9 Expected stock price volatility 62 % 63 % Expected dividend yield 0 % 0 % The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted under both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, which requires the Company to make certain estimates and assumptions, with the weighted-average valuation assumptions for stock-based awards, as follows: weighted-average risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period commensurate with the assumed expected option term; expected term of stock options represents the period of time stock options are expected to be outstanding, which for employees is the expected term derived using the simplified method and for non-employees is the contractual term; expected stock price volatility is based on historical stock price volatilities of similar entities within the Company’s industry over the period commensurate with the expected term of the stock option; and, expected dividend yield is based on annual dividends of $0.00 as the Company has not historically paid, and does not expect to pay dividends for the foreseeable future.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 10 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total June 30, 2019 Senior Secured Convertible Note $ — $ — $ 6,790,096 $ 6,790,096 Totals $ — $ — $ 6,790,096 $ 6,790,096 December 31, 2018 Senior Secured Convertible Note $ — $ — $ 7,903,000 $ 7,903,000 Totals $ — $ — $ 7,903,000 $ 7,903,000 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. Senior Secured Convertible Note The Senior Convertible Note estimated fair value and face value principal, and the corresponding changes in estimated fair value and face value principal payable, as of each of the respective dates noted, are as follows: Face Value Principal Senior Secured Convertible Note - Six Months Ended June 30, 2019 Fair Value Payable Balances - December 31, 2018 $ 7,903,000 $ 7,750,000 Less: repayment - bi-monthly Installment Amount - common stock (193,750 ) (193,750 ) Less: repayment - Accelerated Installment Amount - common stock (23,250 ) (23,250 ) Less: repayment - voluntary conversion price adjustments - common stock (1,314,000 ) (1,314,000 ) Less: bi-monthly non-installment payments - cash (279,002 ) — Less: bi-monthly non-installment payments - common stock (22,961 ) — Fair value adjustment - six months ended June 30, 2019 720,059 — Balances - June 30, 2019 $ 6,790,096 $ 6,219,000 In the six months ended June 30, 2019, the aggregate face value principal repayments of $1,531,000 and $22,961 of corresponding non-installment payments were settled by the issue of a total of 1,516,241 shares of common stock of the Company, and an additional $279,002 of the non-installment payments were cash paid. The fair value adjustments of $720,059 as of June 30, 2019 was recognized as a current period expense, as no portion of such fair value adjustments resulted from instrument-specific credit risk of the Senior Convertible Note, as of the dates noted. The estimated fair value of the Senior Convertible Note as of June 30, 2019 was computed using a combination of the present value of the Senior Convertible Note cash flows using a synthetic credit rating analysis’ required rate of return and the Black-Scholes option pricing model, using the following assumptions: Fair Value Assumptions June 30, Senior Secured Convertible Note 2019 Fair value $ 6,790,096 Face value principal payable $ 6,219,000 Required rate of return 11.1 % Conversion price $ 1.60 Value of common stock $ 1.14 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 % See Note 12, Debt

Debt

Debt	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt	Note 11 — Debt Senior Secured Convertible Note In a private placement transaction with an institutional investor (“Investor”, “Lender”, and /or “Holder”) on December 27, 2018, the Company entered into a Securities Purchase Agreement under which it issued a Senior Secured Convertible Note, having an issue date of December 27, 2018, a contractual maturity date of December 31, 2020, a face value principal of $7.75 million, and a stated interest rate of 7.875% per annum - the “Senior Convertible Note”. Bi-Monthly Payments & Conversion The Senior Convertible Note requires bi-monthly payments on the 15th calendar day and the last trading day of the month, commencing January 15, 2019 and ending December 31, 2020, including a contractually stated face value principal repayment, referred to as a bi-monthly Installment Amount, and a payment based on the outstanding face value principal and the 7.875% annual interest rate, referred to herein as a bi-monthly non-installment payment. The bi-monthly payments of January 15, 2019 through June 15, 2019 were non-installment payments only, and the bi-monthly payments from June 28, 2019 through December 31, 2020 include both the Installment Amount and the non-installment payment. The Senior Convertible Note Installment Amount includes 35 bi-monthly payments of $193,750 from June 28, 2019 through November 30, 2020, and two final payments of $484,375 on each of December 15, 2020 and December 31, 2020, with such bi-monthly dates referred to as Installment Dates. Notwithstanding, future contractual Installment Amounts are reduced by additional face value principal repayments, with the reductions applied in reverse order of maturity of the bi-monthly Installment Amounts, starting with the final December 31, 2020 bi-monthly Installment Amount. In this regard, as of June 30, 2019, the future bi-monthly Installment Amounts have been reduced by an aggregate of $1,337,250 resulting from conversions in excess of the contractual bi-monthly Installment Amount, including a series of “conversion price voluntary adjustments” and the “Accelerated Installment Amount”, each as discussed below. At the election of the Holder, at any time after the December 27, 2018 issue date, the Senior Convertible Note may be converted into shares of common stock of the Company at an initial contractual conversion price of $1.60 per share. As amended on April 11, 2019, commencing with the June 28, 2019 bi-monthly payment, the bi-monthly Installment Amount and non-installment payment will be paid by the issue of shares of common stock of the Company, subject to the satisfaction of customary equity conditions, including minimum price and volume thresholds, referred to as an Installment Conversion. In addition to the bi-monthly Installment Amount, the Holder may elect to accelerate the conversion of future bi-monthly Installment Amounts, and interest thereon, referred to herein as an Acceleration Installment Amount, utilizing the then current conversion price of the most recent bi-monthly Installment Conversion, with such Accelerated Installment Amount subject to certain restrictions, as defined. The Senior Convertible Note provides for a voluntary adjustment of the conversion price by at the discretion of the Company, with the consent of the Holder, wherein during the term of the Senior Convertible Note, the Company may at any time reduce the then current conversion price to any amount and for any period of time deemed appropriate by the board of directors of the Company. The Company’s board of directors have adopted guidelines surrounding such a Senior Convertible Note voluntary adjustment of the conversion price, if any, to be implemented by management when favorable market conditions exist for the Company to orderly and effectively reduce its outstanding debt to the investor. See below for a discussion of the conversion price voluntary adjustments. Measurement and Recognition The Senior Convertible Note is a debt host containing embedded features and /or options generally required to be bifurcated from the debt host and recognized as separate derivatives subject to initial and subsequent periodic estimated fair value measurements under FASB Topic ASC 815, Derivatives and Hedging Financial Instruments Financial Instruments Fair Value Measurements In the three and six months ended June 30, 2019, the Company recognized a debt extinguishment loss of $258,811 and $259,812, respectively, resulting from the difference between the face value principal and corresponding non-installment payments, as noted above, and the fair value of the shares of common stock issued upon conversion, with such fair value measured as the respective issue date closing quoted price per share of the common stock of the Company. Subsequent to June 30, 2019: with respect to the July 15, 2019 and July 31, 2019 bi-monthly payments, total Installment Amount of face value principal repayment of $387,500 and the corresponding $38,909 of bi-monthly non-installment payments were settled by the issue of a total of 491,773 shares of common stock of the Company, with a fair value of $506,497. Additionally through August 12, 2019, total Acceleration Installment Amount face value principal repayments of $380,500 and the corresponding $328 of non-installment payment, was settled by the issue of 430,156 shares of common stock of the Company with a fair value of $454,795, with the common stock fair value measured as the respective issue date closing quoted price per share of the common stock of the Company. Covenants and Other Provisions The Company is subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets, and to have an unrestricted cash balance of at least $1.75 million at each quarterly balance sheet date, among other provisions and covenants, including: * Through June 28, 2019, to the extent any portion of the Senior Convertible Note face value principal remains outstanding, the Company may not consummate the sale of any equity or equity-linked security at a price per share less than the initial conversion price of the Senior Convertible Note, without the consent of the Holder. After June 28, 2019, if any portion of the Senor Convertible Note remains outstanding, the Company may consummate the sale of any equity or equity-linked security provided the price per share is equal to or greater than the initial conversion price of the Senior Convertible Note and the aggregate consideration is less than or equal to $5.0 million and compliance with the terms and conditions of the Senior Convertible Note as to the acceleration of Installment Repayments after giving effect to such issuance. These restrictions were waived by the Holder on April 11, 2019. * The Company agreed to hold a stockholder meeting by no later than June 28, 2019 to approve stockholder resolutions with respect to each of: approving an increase in the authorized shares of common stock of the Company to 100 million shares from the current 75 million shares; and approving the issuance of shares of common stock of the Company in connection with the Senior Convertible Note for the purposes of compliance with the stockholder approval rules of The Nasdaq Stock Market (“Nasdaq”). On June 26, 2019, the Company’s stockholders approved the Senior Convertible Note private placement transaction and also approved the increase to 100 million authorized shares. * During the three year period ended December 27, 2021, the Senior Convertible Note private placement investor may participate up to 50%, in future equity and equity-linked securities offered by the Company. The Company will not effect or enter an agreement to effect any variable rate transaction. On each of April 11, 2019, May 8, 2019, and June 25, 2019, the Investor waived the right to participate in the registered offerings of common stock of the Company in April, May, and June 2019, as such registered offerings are discussed in Note 14, Stockholders’ Equity and Common Stock Purchase Warrants Senior Secured Note Interest expense recognized for the previous Senior Secured Note, which was repaid-in-full on December 27, 2018, was a total of $500,304 and $1,000,608 in the three and six months ended June 30, 2018, respectively, and was comprised of $194,570 with respect to the 15% interest expense and $305,734 related to the amortization of the debt discount, during the three months ended June 30, 2019; and, $389,141 with respect to the 15% interest expense and $611,467 related to the amortization of the debt discount, during the six months ended June 30, 2019.

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Preferred Stock	Note 12 — Preferred Stock The Company is authorized to issue 20 million shares of its preferred stock, par value of $0.001 per share, with such designation, rights, and preferences as may be determined from time-to-time by the Company’s board of directors. There were 1,113,201 and 1,069,941 shares of Series B Convertible Preferred Stock (classified in permanent equity) issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. The Series B Convertible Preferred Stock is equity-classified, has a par value of $0.001 per share, no voting rights, a stated value of $3.00 per share, and is immediately convertible upon its issuance. At the holders’ election, a share of Series B Convertible Preferred Stock is convertible into a number of shares of common stock of the Company at a common stock conversion exchange factor equal to a numerator and denominator of $3.00, with each such numerator and denominator not subject to further adjustment, except for the effect of stock dividends, stock splits or similar events affecting the Company’s common stock. The Series B Convertible Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Convertible Preferred Stock. The PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”), provides for dividends at a rate of 8% per annum based on the $3.00 per share stated value of the Series B Convertible Preferred Stock, with such dividends compounded quarterly, accumulate, and are payable in arrears upon being declared by the Company’s board of directors. The Series B Convertible Preferred Stock dividends from April 1, 2018 through October 1, 2021 are payable-in-kind (“PIK”) in additional shares of Series B Convertible Preferred Stock. The dividends may be settled after October 1, 2021, at the option of the Company, through any combination of the issuance of additional Series B Convertible Preferred Stock, shares of common stock, and /or cash payment. The Series B Convertible Preferred Stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders as applicable for each of the periods presented. As of the six months ended June 30, 2019, the Company’s board-of-directors have declared Series B Convertible Preferred Stock dividend payments totaling $129,678 which have been settled by the issue of 43,260 shares of Series B Convertible Preferred Stock, including: dividends earned as of December 31, 2018 and payable January 1, 2019 of $64,197 settled by the issue of 21,413 shares; and dividends earned as of March 31, 2019 and payable April 1, 2019 of $65,481 settled by the issue of 21,847 shares. Subsequently, in August 2019, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend payment earned as of June 30, 2019 and payable July 1, 2019 of $66,792 to be settled by the issue of 22,281 shares of Series B Convertible Preferred Stock. The July 1, 2019 Series B Convertible Preferred Stock dividend payment was not recognized as a dividend payable liability in the accompanying unaudited condensed consolidated balance sheet as the Company’s board of directors had not declared such dividends payable as of June 30, 2019.

Stockholders' Equity and Common

Stockholders' Equity and Common Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity and Common Stock Purchase Warrants	Note 13 — Stockholders’ Equity and Common Stock Purchase Warrants Common Stock As of June 30, 2019 the Company is authorized to issue up to 100.0 million shares of common stock, par value of $0.001 per share. There were 34,139,220 and 27,142,979 shares of common stock issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, summarized as follows: Shares of Common Stock Issued and Outstanding Issued and outstanding as of December 31, 2018 27,142,979 Registered offerings 5,480,000 Senior Secured Convertible Note conversion 1,516,241 Issued and outstanding as of June 30, 2019 34,139,220 ● During the six months ended June 30, 2019, a total of 5,480,000 shares of common stock of the Company were issued in registered offerings, including 4,950,000 shares issued under common stock share subscription agreements entered into with individual investors and 530,000 shares issued under a placement agency agreement, resulting in total proceeds of $5,480,000, before placement agent fees and legal fees of $101,098. ● During the six months ended June 30, 2019, 1,516,241 shares of common stock of the Company were issued upon (partial) conversions of the Senior Secured Convertible Note. See Note 11, Debt, Subsequent to June 30, 2019, through August 12, 2019, an additional 921,929 shares of common stock of the Company were issued upon (partial) conversions of the Senior Secured Convertible Note. See Note 11, Debt, Common Stock Purchase Warrants The following table summarizes outstanding warrants to purchase common stock of the Company at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted Average Average June 30, Exercise December 31, Exercise Expiration 2019 Price /Share 2018 Price Date Equity classified warrants Series Z Warrants 16,815,039 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants 1,199,383 $ 0.01 1,199,383 $ 0.01 June 2032 Total 18,449,240 $ 1.57 18,449,240 $ 1.57 Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Six Months Ended Year Ended June 30, December 31, 2019 2018 NCI - equity (deficit) - beginning of period $ (161,512 ) $ — Investment in majority-owned subsidiary — 1,812 Net loss attributable to NCI (314,273 ) (204,072 ) Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation 133,058 40,748 NCI - equity (deficit) - end of period $ (342,727 ) $ (161, 512 ) The noncontrolling interest presented above is with respect to Lucid Diagnostics Inc., a majority-owned subsidiary of PAVmed Inc., formed in May 2018 in connection with the “CWRU License Agreement”. As of June 30, 2019 and December 31, 2018, there were 10.0 million shares of common stock of Lucid Diagnostics Inc. issued and outstanding, of which PAVmed Inc. holds a 81.875% majority-interest ownership and has a controlling financial interest, with the remaining 18.125% minority-interest ownership held by CWRU and each of the three physician inventors of the of the intellectual property and proprietary technologies underlying the CWRU License Agreement. Accordingly, a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity, along with the recognition of a net loss attributable to the NCI. See Note 7, Agreements Related to Acquired Intellectual Property Rights Stock-Based Compensation

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Loss Per Share	Note 14 —Loss Per Share The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Numerator Net loss - as reported, before noncontrolling interest $ (3,739,133 ) $ (5,146,540 ) $ (7,442,746 ) $ (7,971,909 ) Net loss attributable to noncontrolling interest 145,522 81,200 314,273 81,200 Net loss - as reported, attributable to PAVmed Inc. $ (3,593,611 ) $ (5,065,340 ) $ (7,128,473 ) $ (7,890,709 ) Convertible Preferred Stock dividends (1) Series B $ (66,792 ) $ (63,623 ) $ (132,273 ) $ (74,029 ) Series A-1 — — — (25,148 ) Series A — — — (26,487 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock — — — (726,531 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock — — — 199,241 Net loss attributable to PAVmed Inc. common stockholders $ (3,660,403 ) $ (5,128,963 ) $ (7,260,746 ) $ (8,543,663 ) Denominator Weighted-average common shares outstanding basic and diluted (2)(3) 27,605,881 19,289,874 27,343,912 17,924,632 Loss per share Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. $ (0.13 ) $ (0.26 ) $ (0.26 ) $ (0.44 ) - Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.27 ) $ (0.27 ) $ (0.48 ) (1) The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to June 30, 2018, and each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. See Note 12, Preferred Stock (2) Basic weighted-average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. (3) The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses. The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: June 30, 2019 2018 Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan 5,803,529 3,082,032 Unit purchase options - “UPO-Z” /”UPO-W” - as to shares of common stock 53,000 53,000 Unit purchase options - “UPO-Z” - as to shares underlying Series Z Warrants 53,000 — Unit purchase options - “UPO-W” - as to shares underlying Series W Warrants — 53,000 Series Z Warrants 16,815,039 16,815,039 Series W Warrants 381,818 381,818 Series S Warrants 1,199,383 1,199,383 Series B Convertible Preferred Stock 1,113,201 975,568 Total 25,418,970 22,559,840

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 15 — Subsequent Events Other Matters Except as otherwise noted herein, the Company has evaluated subsequent events through the date of filing of this Quarterly Report on Form 10-Q and determined there to be no further events requiring adjustments to the unaudited condensed unaudited condensed consolidated financial statements and /or disclosures therein.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the minority ownership interest in the Company’s majority-owned subsidiary Lucid Diagnostics Inc. and the corresponding noncontrolling interest. The condensed balance sheet as of December 31, 2018, which has been derived from audited financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial information. Certain items have been reclassified to conform to the current period presentation. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and related notes thereto as of and for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC.
Going Concern	Going Concern During the six months ended June 30, 2019, the Company incurred a loss attributable to PAVmed common stockholders of $7.3 million, and negative cash flows from operating activities of $6.4 million. As of June 30, 2019, the Company had negative working capital of $1.9 million inclusive of approximately $6.8 million of the estimated fair value of the Senior Secured Convertible Note classified as a current liability and approximately $6.9 million of cash. The Company anticipates incurring operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating losses as it completes the development of its products, seeks regulatory approvals and clearances of such products, and begin to commercially market such products. These factors, which have existed since inception, are expected to continue, and raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued. The Company’s ability to fund its operations is dependent upon management’s plans, which include raising additional capital, refinance the debt upon maturity, obtaining regulatory approvals for its products currently under development, commercializing and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance the Company will be successful in these efforts. The Company’s unaudited condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern
Recent Accounting Pronouncements	Recent Accounting Pronouncements Adoption of new accounting principles In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) Recently issued accounting pronouncements, not yet adopted: In June 2018, the FASB issued its Accounting Standards Update (“ASU”) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07), which, upon the effective date, will result in non-employee stock-based compensation to be within the scope of ASC-718, and will supersede ASC 505-50. A principal change of the new guidance is to eliminate the ASC 505-50 required periodic fair value remeasure (“mark-to-market”) and use of the “contractual term” as an input to the Black-Scholes option pricing model to calculate the estimated fair value of stock options issued to non-employees, in favor of the ASC 718 one-time measurement of the grant date fair value and use of an “expected term” as such valuation input, for non-employee stock-based compensation expense, as is currently done for employee stock-based compensation expense. The amended ASC-718 non-employee stock-based compensation provisions are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within such fiscal year, and for all other companies for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606). With respect to the Company and its majority-owned subsidiary, the amended ASC-718 non-employee stock-based compensation provisions are required to be adopted by no later than January 1, 2020, resulting from the Company’s “JOBS Act EGC Election” as discussed Company’s Annual Report of Form 10-K for the year ended December 31, 2018. Additionally, the Company, under its “JOBS Act EGC Accounting Standards Election”, adopted ASC 606 as of January 1, 2019, which is the required adoption date of ASC 606 for private companies. At this time, the Company and its majority-owned subsidiary continue to apply the guidance of ASC-505-50 with respect to non-employee stock-based compensation, subject-to the future adoption date of the amended ASC-718 provisions with respect to non-employee stock-based compensation. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) - Part I - Accounting for Certain Financial Instruments with Down-Round Features, and Part II - Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: June 30, December 31, 2019 2018 Security deposits $ 14,250 $ 14,250 Advanced payments to service providers and suppliers 83,326 223,790 Total prepaid expenses and other current assets $ 97,576 $ 238,040

Equipment, Net (Tables)

Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Equipment, Net	June 30, December 31, 2019 2018 Research and development equipment $ 62,590 $ 40,380 Computer equipment 19,432 16,584 Equipment, gross 82,022 56,964 Less: accumulated depreciation (27,242 ) (20,693 ) Equipment, net $ 54,780 $ 36,271

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Accrued Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of: June 30, December 31, 2019 2018 Bonus $ 115,400 $ 873,621 Payroll — 145,937 Vacation 102,180 38,763 Employee Stock Purchase Plan 15,381 — License agreement fee 222,553 222,553 Milestone payment 75,000 — Operating expenses 191,933 49,872 Total accrued expenses and other current liabilities $ 722,447 $ 1,330,746

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	PAVmed Inc 2014 Equity Plan - Stock Options Weighted Number Average Aggregate Stock Exercise Intrinsic PAVmed Inc. 2014 Equity Plan - Stock Options Options Price Value Outstanding stock options at December 31, 2018 3,327,140 $ 4.40 Granted 1,825,000 $ 1.00 Exercised — $ — Forfeited (48,611 ) $ 5.00 Outstanding stock options at June 30, 2019 5,103,529 $ 2.71 $ 257,500 Vested and exercisable stock options at June 30, 2019 2,620,019 $ 3.83 $ 43,292 Unvested stock options at June 30, 2019 2,483,510 $ 1.53 $ 214,208 Lucid Diagnostics Inc 2018 Equity Plan - Stock Options Weighted Number Average Stock Exercise Lucid Diagnostics Inc. 2018 Equity Plan - Stock Options Options Price Outstanding stock options at December 31, 2018 375,000 $ 0.60 Granted 400,000 $ 1.00 Exercised — $ — Forfeited — $ Outstanding stock options at June 30, 2019 775,000 $ 0.81 Vested and exercisable stock options at June 30, 2019 374,999 $ 0.83 Unvested stock options at June 30, 2019 400,001 $ 0.78
Schedule of Stock-Based Compensation Awards Granted	Consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards, for the periods indicated, was as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 General and administrative expenses $ 299,346 $ 233,962 $ 584,009 $ 453,356 Research and development expenses 89,017 69,928 263,040 121,820 Total $ 388,363 $ 303,890 $ 847,049 $ 575,176
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized for PAVmed Inc. stock options granted to employees and members of the board of directors was based on a weighted average estimated fair value of $0.93 and $1.23 per share of PAVmed Inc. common stock, during the six months ended June 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 2018 Risk free interest rate 2.3 % 2.0 % Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 50 % 50 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to employees during the three and six months ended June 30, 2019 was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 Risk free interest rate 2.3 % Expected term of stock options (in years) 5.8 Expected stock price volatility 63 % Expected dividend yield 0 %
Non-employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Stock-based compensation expense recognized for PAVmed Inc. stock options granted to non-employees was based on a weighted average estimated fair value of $1.90 and $1.96 per share of PAVmed Inc. common stock, during the six months ended June 30, 2019 and 2018, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, 2019 2018 Risk free interest rate 2.3 % 2.6 % Expected term of stock options (in years) 8.7 9.0 Expected stock price volatility 60 % 60 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized for Lucid Diagnostics Inc. stock options granted to non-employees during the six months ended June 30, 2019 and 2018 was calculated using the following weighted average Black-Scholes valuation model assumptions: Six Months Ended June 30, June 30, 2019 2018 Risk free interest rate 2.2 % 2.9 % Expected term of stock options (in years) 9.1 9.9 Expected stock price volatility 62 % 63 % Expected dividend yield 0 % 0 %

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Schedule of Financial Liabilities Measured at Fair Value On Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at Reporting Date Using (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total June 30, 2019 Senior Secured Convertible Note $ — $ — $ 6,790,096 $ 6,790,096 Totals $ — $ — $ 6,790,096 $ 6,790,096 December 31, 2018 Senior Secured Convertible Note $ — $ — $ 7,903,000 $ 7,903,000 Totals $ — $ — $ 7,903,000 $ 7,903,000 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.
Schedule of Fair Value Assumption Used	The estimated fair value of the Senior Convertible Note as of June 30, 2019 was computed using a combination of the present value of the Senior Convertible Note cash flows using a synthetic credit rating analysis’ required rate of return and the Black-Scholes option pricing model, using the following assumptions: Fair Value Assumptions June 30, Senior Secured Convertible Note 2019 Fair value $ 6,790,096 Face value principal payable $ 6,219,000 Required rate of return 11.1 % Conversion price $ 1.60 Value of common stock $ 1.14 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 %
Senior Secured Convertible Note [Member]
Schedule of Senior Convertible Note Estimated Fair Value and Changes in Face Value Principal Payable	The Senior Convertible Note estimated fair value and face value principal, and the corresponding changes in estimated fair value and face value principal payable, as of each of the respective dates noted, are as follows: Face Value Principal Senior Secured Convertible Note - Six Months Ended June 30, 2019 Fair Value Payable Balances - December 31, 2018 $ 7,903,000 $ 7,750,000 Less: repayment - bi-monthly Installment Amount - common stock (193,750 ) (193,750 ) Less: repayment - Accelerated Installment Amount - common stock (23,250 ) (23,250 ) Less: repayment - voluntary conversion price adjustments - common stock (1,314,000 ) (1,314,000 ) Less: bi-monthly non-installment payments - cash (279,002 ) — Less: bi-monthly non-installment payments - common stock (22,961 ) — Fair value adjustment - six months ended June 30, 2019 720,059 — Balances - June 30, 2019 $ 6,790,096 $ 6,219,000

Stockholders' Equity and Comm_2

Stockholders' Equity and Common Stock Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding	Shares of Common Stock Issued and Outstanding Issued and outstanding as of December 31, 2018 27,142,979 Registered offerings 5,480,000 Senior Secured Convertible Note conversion 1,516,241 Issued and outstanding as of June 30, 2019 34,139,220
Schedule of Outstanding Warrants to Purchase Common Stock	The following table summarizes outstanding warrants to purchase common stock of the Company at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted Average Average June 30, Exercise December 31, Exercise Expiration 2019 Price /Share 2018 Price Date Equity classified warrants Series Z Warrants 16,815,039 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants 1,199,383 $ 0.01 1,199,383 $ 0.01 June 2032 Total 18,449,240 $ 1.57 18,449,240 $ 1.57
Schedule of Noncontrolling Interest	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows: Six Months Ended Year Ended June 30, December 31, 2019 2018 NCI - equity (deficit) - beginning of period $ (161,512 ) $ — Investment in majority-owned subsidiary — 1,812 Net loss attributable to NCI (314,273 ) (204,072 ) Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation 133,058 40,748 NCI - equity (deficit) - end of period $ (342,727 ) $ (161, 512 )

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Numerator Net loss - as reported, before noncontrolling interest $ (3,739,133 ) $ (5,146,540 ) $ (7,442,746 ) $ (7,971,909 ) Net loss attributable to noncontrolling interest 145,522 81,200 314,273 81,200 Net loss - as reported, attributable to PAVmed Inc. $ (3,593,611 ) $ (5,065,340 ) $ (7,128,473 ) $ (7,890,709 ) Convertible Preferred Stock dividends (1) Series B $ (66,792 ) $ (63,623 ) $ (132,273 ) $ (74,029 ) Series A-1 — — — (25,148 ) Series A — — — (26,487 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock — — — (726,531 ) Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock — — — 199,241 Net loss attributable to PAVmed Inc. common stockholders $ (3,660,403 ) $ (5,128,963 ) $ (7,260,746 ) $ (8,543,663 ) Denominator Weighted-average common shares outstanding basic and diluted (2)(3) 27,605,881 19,289,874 27,343,912 17,924,632 Loss per share Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. $ (0.13 ) $ (0.26 ) $ (0.26 ) $ (0.44 ) - Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.27 ) $ (0.27 ) $ (0.48 ) (1) The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to June 30, 2018, and each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. See Note 12, Preferred Stock (2) Basic weighted-average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. (3) The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: June 30, 2019 2018 Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan 5,803,529 3,082,032 Unit purchase options - “UPO-Z” /”UPO-W” - as to shares of common stock 53,000 53,000 Unit purchase options - “UPO-Z” - as to shares underlying Series Z Warrants 53,000 — Unit purchase options - “UPO-W” - as to shares underlying Series W Warrants — 53,000 Series Z Warrants 16,815,039 16,815,039 Series W Warrants 381,818 381,818 Series S Warrants 1,199,383 1,199,383 Series B Convertible Preferred Stock 1,113,201 975,568 Total 25,418,970 22,559,840

The Company and Description o_2

The Company and Description of the Business (Details Narrative)	6 Months Ended
	Jun. 30, 2019Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Net loss attributable to common stockholders	$ (3,660,403)	$ (5,128,963)	$ (7,260,746)	$ (8,543,663)
Net cash flows used in operating activities			(6,388,893)	$ (3,902,149)
Working capital	1,900,000		1,900,000
Principal balance of debt	6,219,000		6,219,000		$ 775,000
Cash	6,900,000		6,900,000
Senior Secured Covertible Notes [Member]
Principal balance of debt	$ 6,800,000		$ 6,800,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expense and Other Assets, Current [Abstract]
Security deposits	$ 14,250	$ 14,250
Advanced payments to service providers and suppliers	83,326	223,790
Total prepaid expenses and other current assets	$ 97,576	$ 238,040

Equipment, Net (Details Narrati

Equipment, Net (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,281	$ 1,802	$ 6,549	$ 3,605

Equipment, Net - Schedule of Eq

Equipment, Net - Schedule of Equipment, Net (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 82,022	$ 56,964
Less: accumulated depreciation	(27,242)	(20,693)
Equipment, net	54,780	36,271
Research and Development Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	62,590	40,380
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 19,432	$ 16,584

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued Liabilities [Abstract]
Bonus	$ 115,400	$ 873,621
Payroll		145,937
Vacation	102,180	38,763
Employee Stock Purchase Plan	15,381
License Agreement fee	222,553	222,553
Milestone payment	75,000
Operating expenses	191,933	49,872
Total accrued expenses and other current liabilities	$ 722,447	$ 1,330,746

Agreements Related to Acquire_2

Agreements Related to Acquired Intellectual Property Rights (Details Narrative) - USD ($)	May 12, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Research and development expense		$ 1,405,060	$ 1,148,811	$ 2,856,010	$ 1,712,029
Lucid Diagnostics Inc [Member]
Shares of common stock percentage		81.875%		81.875%		81.875%
CWRU License Agreement [Member] | Research and Development Expense [Member]
Reimbursement of patent fees		$ 47,186		$ 78,148
CWRU License Agreement [Member] | Lucid Diagnostics Inc [Member]
Accrued license fee	$ 273,000
License fee as an initial requirement	50,000
Payment of intellectual property	$ 50,000
Description of intellectual property payment	Quarterly payments of $50,000 until such fee is paid-in-full, provided, however, the commencement of such quarterly payments is subject to Lucid Diagnostics Inc. consummation of a bona fide financing with an unrelated third-party in excess of $500,000.
Description of equity interest percentage	The right, in its sole discretion, to require the Company to transfer to CWRU a percentage, varying up to 100%, of the shares of common stock of Lucid Diagnostics Inc.
Shares of common stock percentage	100.00%
Research and development expense	$ 75,000
Tufts Patent License Agreement [Member]
Reimbursement of patent fees		$ 29,390	$ 25,876	$ 33,258	$ 61,713

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Management Services Agreement [Member] | HCP/Advisors LLC [Member]
Related Party Transaction [Line Items]
Fees incurred	$ 75,000	$ 150,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Lease Agreement [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Percentage of increase in monthly rent			5.00%
Description monthly lease payment			Month-to-month basis, with a 5% per annum increase in the monthly lease payment effective February 1 of each year, and the lease agreement may be cancelled with three months written notice.
Rent expense	$ 32,992	$ 62,344	$ 65,461	$ 31,421

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)

Jun. 03, 2019

Apr. 02, 2019

Mar. 15, 2019

Jun. 30, 2019

May 31, 2019

Apr. 30, 2019

Feb. 28, 2018

Jun. 30, 2019

Mar. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

$ 388,363

$ 303,890

$ 847,049

$ 575,176

Lucid Diagnostics Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total unrecognized stock-based compensation expense

$ 200,000

200,000

$ 200,000

Period for recognition of unrecognized compensation expense

2 years 2 months 12 days

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

$ 61,833

$ 82,444

Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

250,000

Vesting portion of stock

ESPP share purchase dates are April 1 and October 1, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019 with a corresponding share purchase date of October 1, 2019.

Purchase price per share percentage on ESPP plan

85.00%

2014 Long Term Incentive Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock authorized

7,951,081

7,951,081

7,951,081

Shares of common stock available for grant of stock options

2,648,406

2,648,406

2,648,406

Number of shares granted outside

500,854

500,854

500,854

Number of options granted

1,825,000

Exercise price per share

$ 1

Contractual term of stock options

10 years

Number of stock options forfeited

48,611

48,611

Weighted average remaining contractual term of stock options outstanding

8 years 7 months 6 days

Weighted average remaining contractual term of stock options vested and exercisable

7 years 9 months 18 days

Total unrecognized stock-based compensation expense

$ 1,700,000

$ 1,700,000

$ 1,700,000

Period for recognition of unrecognized compensation expense

1 year 6 months

2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting portion of stock

Annual basis, commencing March 15, 2020 and ending March 15, 2022

Number of restricted stock award granted

700,000

Number of restricted stock award granted, value

$ 742,000

2014 Long Term Incentive Equity Plan [Member] | Non-Executive Members of Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

800,000

Exercise price per share

$ 1

Vesting portion of stock

Quarterly basis commencing March 31, 2019 and ending December 31, 2021

2014 Long Term Incentive Equity Plan [Member] | Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

950,000

Vesting portion of stock

Quarterly basis commencing March 31, 2019 and ending December 31, 2021

Weighted average fair value of stock options

$ 1.90

$ 1.96

2014 Long Term Incentive Equity Plan [Member] | Non-employee Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

25,000

Exercise price per share

$ 1.10

Vesting portion of stock

Quarterly basis commencing June 30, 2019 and ending March 31, 2022

2014 Long Term Incentive Equity Plan [Member] | New Hire Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

50,000

Exercise price per share

$ 1.08

Vesting portion of stock

Quarterly basis commencing June 30, 2019 and ending March 31, 2022

2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average fair value of stock options

$ 0.93

$ 1.23

2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

4,202

3,633

$ 8,305

$ 3,633

2018 Long Term Incentive Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total unrecognized stock-based compensation expense

$ 700,000

$ 700,000

$ 700,000

Period for recognition of unrecognized compensation expense

2 years 8 months 12 days

2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock authorized

2,000,000

2,000,000

2,000,000

Shares of common stock available for grant of stock options

1,525,000

1,525,000

1,525,000

Number of options granted

300,000

Weighted average remaining contractual term of stock options outstanding

9 years 3 months 19 days

Weighted average remaining contractual term of stock options vested and exercisable

9 years 3 months 19 days

Expected dividend yield

$ 0

2018 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense

$ 28,555

$ 8,277

$ 133,058

$ 8,277

2018 Long-Term Incentive Equity Plan [Member] | Vesting Immediately [Member] | Lucid Diagnostics Inc [Member] | February 18, 2019 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

400,000

Exercise price per share

$ 1

Vesting portion of stock

Vesting immediately

Weighted average remaining contractual term of stock options outstanding

10 years

2018 Long-Term Incentive Equity Plan [Member] | Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

100,000

300,000

Exercise price per share

$ 1

Vesting portion of stock

Vesting immediately

2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting Immediately [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

200,000

2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting on a Quarterly Basis [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

100,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details) - USD ($)	1 Months Ended	6 Months Ended
	Apr. 30, 2019	Jun. 30, 2019
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		3,327,140
Number of Stock Options, Granted		1,825,000
Number of Stock Option, Exercised
Number of Stock Option, Forfeited	(48,611)	(48,611)
Number of Stock Options Outstanding, Ending Balance		5,103,529
Number of Stock Options Vested and exercisable		2,620,019
Number of Stock Options Unvested		2,483,510
Weighted-Average Exercise Price, Beginning		$ 4.4
Weighted-Average Exercise Price, Granted		1
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Forfeited		5
Weighted-Average Exercise Price, Ending Balance		2.71
Weighted-Average Exercise Price, Vested and exercisable		3.83
Weighted-Average Exercise Price, Unvested		$ 1.53
Aggregate Intrinsic Value Outstanding		$ 257,500
Aggregate Intrinsic Value Vested and exercisable		43,292
Aggregate Intrinsic Value Unvested		$ 214,208
2018 Stock Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		375,000
Number of Stock Options, Granted		400,000
Number of Stock Option, Exercised
Number of Stock Option, Forfeited
Number of Stock Options Outstanding, Ending Balance		775,000
Number of Stock Options Vested and exercisable		374,999
Number of Stock Options Unvested		400,001
Weighted-Average Exercise Price, Beginning		$ 0.6
Weighted-Average Exercise Price, Granted		1
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Ending Balance		0.81
Weighted-Average Exercise Price, Vested and exercisable		0.83
Weighted-Average Exercise Price, Unvested		$ 0.78

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 388,363	$ 303,890	$ 847,049	$ 575,176
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	299,346	233,962	584,009	453,356
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 89,017	$ 69,928	$ 263,040	$ 121,820

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
2014 Long Term Incentive Equity Plan [Member] | Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.30%	2.60%
Expected term of stock options (in years)	8 years 8 months 12 days	9 years
Expected stock price volatility	60.00%	60.00%
Expected dividend yield	0.00%	0.00%
2014 Long Term Incentive Equity Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.30%
Expected term of stock options (in years)	5 years 9 months 18 days
Expected stock price volatility	63.00%
Expected dividend yield	0.00%
2018 Long-Term Incentive Equity Plan [Member] | Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.20%	2.90%
Expected term of stock options (in years)	9 years 1 month 6 days	9 years 10 months 25 days
Expected stock price volatility	62.00%	63.00%
Expected dividend yield	0.00%	0.00%

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - Securities Purchase Agreement [Member] - Senior Secured Convertible Note [Member]	6 Months Ended
	Jun. 30, 2019USD ($)shares
Repayments of debt	$ 1,531,000
Non installment payments settles by shares	$ 22,961
Non installment payments settles - common shares | shares	1,516,241
Additional non installment payments in cash	$ 279,002
Fair value of adjustment of convertible debt	$ 720,059

Financial Instruments Fair Va_4

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value On Recurring Basis (Details) - USD ($)		Jun. 30, 2019	Dec. 31, 2018
Fair value of liability	[1]	$ 6,790,096	$ 7,903,000
Senior Secured Note [Member]
Fair value of liability	[1]	6,790,096	7,903,000
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | Senior Secured Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | Senior Secured Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]	6,790,096	7,903,000
Fair Value, Inputs, Level 3 [Member] | Senior Secured Note [Member]
Fair value of liability	[1]	$ 6,790,096	$ 7,903,000
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.

Financial Instruments Fair Va_5

Financial Instruments Fair Value Measurements - Schedule of Convertible Note Estimated Fair Value and Changes in Face Value Principal Payable (Details) - Senior Secured Convertible Note [Member]	6 Months Ended
	Jun. 30, 2019USD ($)
Fair Value - Beginning	$ 7,903,000
Less: bi-monthly Installment Amount - common stock	(193,750)
Less: repayment - Accelerated Installment Amount - common stock	(23,250)
Less: repayment - voluntary conversion price adjustments - common stock	(1,314,000)
Less: bi-monthly non-installment payments - Cash	(279,002)
Less: bi-monthly non-installment payments - common stock	(22,961)
Fair value adjustment	720,059
Fair Value - Ending	6,790,096
Face Value Principal Payable - Beginning	7,750,000
Less: bi-monthly Installment Amount - common stock	(193,750)
Less: repayment - Accelerated Installment Amount - common stock	(23,250)
Less: repayment - voluntary conversion price adjustments - common stock	(1,314,000)
Less: bi-monthly non-installment payments - Cash
Less: bi-monthly non-installment payments - common stock
Fair value adjustment
Face Value Principal Payable - Ending	$ 6,219,000

Financial Instruments Fair Va_6

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Value of common stock	$ 0.001	$ 0.001
Senior Secured Convertible Note [Member]
Fair value	$ 6,790,096	$ 7,903,000
Face value principal payable	$ 6,219,000	$ 7,750,000
Conversion price	$ 1.60
Value of common stock	$ 1.14
Expected term (years)	1 year 6 months 3 days
Measurement Input, Required Rate of Return [Member] | Senior Secured Convertible Note [Member]
Fair value assumptions, measurement input, percentages	11.10%
Measurement Input, Price Volatility [Member] | Senior Secured Convertible Note [Member]
Fair value assumptions, measurement input, percentages	53.00%
Risk Free Interest Rate [Member] | Senior Secured Convertible Note [Member]
Fair value assumptions, measurement input, percentages	1.80%
Measurement Input, Expected Dividend Rate [Member] | Senior Secured Convertible Note [Member]
Fair value assumptions, measurement input, percentages	0.00%

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Jul. 31, 2019	Jul. 15, 2019	Dec. 27, 2018	Aug. 12, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 26, 2019	Dec. 31, 2018
Repayment of convertible debt							$ 279,002
Reduction in bi-monthly payments resulting from conversion							1,337,250
Change in fair value - Senior Secured Convertible Note					$ (161,108)		(720,059)
Debt extinguishment loss					258,811		259,812
Subsequent Event [Member]
Repayments of debt	$ 387,500	$ 387,500		$ 380,500
Non installment payments settles by shares	$ 38,909	$ 38,909		$ 328
Non installment payments settles - common shares	491,773	491,773		430,156
Fair value of adjustment of convertible debt	$ 506,497	$ 506,497		$ 454,795
June 28, 2019 Through November 30, 2020 [Member]
Bi-monthly installment payments							193,750
December 15, 2020 [Member]
Bi-monthly installment payments							484,375
December 31, 2020 [Member]
Bi-monthly installment payments							484,375
Senior Secured Convertible Note [Member]
Face value principal					$ 6,219,000		$ 6,219,000			$ 7,750,000
Conversion price					$ 1.60		$ 1.60
Senior Secured Note One [Member]
Interest expenses percentage					15.00%
Interest expense					$ 500,304		$ 1,000,608
Comprised interest expenses					194,570
Amortization of debt discount					305,734
15% Interest Expense Senior Secured Note One [Member]
Interest expenses percentage							15.00%
Interest expense							$ 389,141
Amortization of debt discount							611,467
Securities Purchase Agreement [Member]
Covenants and other provisions unrestricted cash balance					$ 1,750,000		1,750,000
Estimated covenants and other provisions maximum aggregate consideration							$ 5,000,000
Covenants and other provisions change in authorized shares of common stock					100,000,000		100,000,000
Securities Purchase Agreement [Member] | Senior Secured Convertible Note [Member]
Debt instrument maturity date			Dec. 31, 2020
Face value principal			$ 7,750,000
Interest rate			7.875%
Annual interest rate on bi-monthly payments			7.875%
Conversion price			$ 1.60
Repayments of debt							$ 1,531,000
Non installment payments settles by shares							$ 22,961
Non installment payments settles - common shares							1,516,241
Covenants and other provisions, description			The Company is subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends, distributions or redemptions, and the transfer of assets, and to have an unrestricted cash balance of at least $1.75 million at each quarterly balance sheet date, among other provisions and covenants
Covenants and other provisions change in authorized shares of common stock			75,000,000						100,000,000

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Jun. 30, 2019	Aug. 31, 2019	Mar. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, shares authorized	20,000,000			20,000,000	20,000,000
Preferred stock par value	$ 0.001			$ 0.001	$ 0.001
Series B Convertible Preferred Stock [Member]
Dividend rate of preferred stock	8.00%
Preferred stock dividend			$ 65,481	$ 129,678	$ 64,197
Preferred stock dividend, settled in shares			21,847	43,260	21,413
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]
Preferred stock dividend		$ 66,792
Preferred stock dividend, settled in shares		22,281
Series B Convertible Preferred Stock [Member]
Preferred stock par value	$ 0.001			$ 0.001	$ 0.001
Convertible preferred stock, shares issued	1,113,201			1,113,201	1,069,941
Preferred stock, shares outstanding	1,113,201			1,113,201	1,069,941
Preferred stock stated value per share	$ 3			$ 3
Common stock conversion exchange factor of denominator	$ 3			$ 3

Stockholders' Equity and Comm_3

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 12, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Common stock, shares authorized		100,000,000		100,000,000		100,000,000
Common stock, par value per share		$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued		34,139,220		34,139,220		27,142,979
Common stock, shares outstanding		34,139,220		34,139,220		27,142,979
Number of shares issued				5,480,000
Gross proceeds from issuance of common stock				$ 5,480,000
Placement agent fees and legal fees				$ 101,098
Senior Secured Convertible Note conversion, shares issued				1,516,241
Stock-based compensation expense		$ 388,363	$ 303,890	$ 847,049	$ 575,176
Lucid Diagnostics Inc [Member]
Common stock, shares issued		10,000,000		10,000,000		10,000,000
Common stock, shares outstanding		10,000,000		10,000,000		10,000,000
Majority ownership interest percentage		81.875%		81.875%		81.875%
Lucid Diagnostics Inc [Member] | Noncontrolling Interest [Member]
Majority ownership interest percentage		18.125%		18.125%		18.125%
Subsequent Event [Member]
Senior Secured Convertible Note conversion, shares issued	921,929
Placement Agency Agreement [Member]
Number of shares issued				530,000
Individual Investors [Member]
Number of shares issued				4,950,000

Stockholders' Equity and Comm_4

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Shares of Common Stock Issued and Outstanding, beginning balance			27,142,979
Registered offerings			5,480,000
Senior Secured Convertible Note conversion			1,516,241
Shares of Common Stock Issued and Outstanding, ending balance	34,139,220		34,139,220
Common Stock [Member]
Shares of Common Stock Issued and Outstanding, beginning balance			27,142,979
Registered offerings			5,480,000	2,649,818
Senior Secured Convertible Note conversion			1,516,241
Shares of Common Stock Issued and Outstanding, ending balance	34,139,220		34,139,220

Stockholders' Equity and Comm_5

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Outstanding Warrants to Purchase Common Stock (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Warrants [Member]
Warrant issued and outstanding	18,449,240	18,449,240
Warrant, weighted average exercise price	$ 1.57	$ 1.57
Equity Classified Warrants [Member] | Series Z Warrants [Member]
Warrant issued and outstanding	16,815,039	16,815,039
Warrant, weighted average exercise price	$ 1.60	$ 1.60
Warrant expiration date	Apr. 30, 2024	Apr. 30, 2024
Equity Classified Warrants [Member] | UPO - Series Z Warrants [Member]
Warrant issued and outstanding	53,000	53,000
Warrant, weighted average exercise price	$ 1.60	$ 1.60
Warrant expiration date	Jan. 31, 2022	Jan. 31, 2022
Equity Classified Warrants [Member] | Series W Warrants [Member]
Warrant issued and outstanding	381,818	381,818
Warrant, weighted average exercise price	$ 5	$ 5
Warrant expiration date	Jan. 31, 2022	Jan. 31, 2022
Equity Classified Warrants [Member] | Series S Warrants [Member]
Warrant issued and outstanding	1,199,383	1,199,383
Warrant, weighted average exercise price	$ 0.01	$ 0.01
Warrant expiration date	Jun. 30, 2032	Jun. 30, 2032

Stockholders' Equity and Comm_6

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
NCI - equity (deficit) - beginning of period			$ (161,512)
Net loss attributable to NCI	$ (145,522)	$ (81,200)	(314,273)	$ (81,200)
NCI - equity (deficit) - end of period	(342,727)		(342,727)		$ (161,512)
Noncontrolling Interest [Member]
NCI - equity (deficit) - beginning of period			(161,512)
Investment in majority-owned subsidiary					1,812
Net loss attributable to NCI			(314,273)		(204,072)
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation			133,058		40,748
NCI - equity (deficit) - end of period	$ (342,727)		$ (342,727)		$ (161,512)

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net loss - as reported, before noncontrolling interest		$ (3,739,133)	$ (5,146,540)	$ (7,442,746)	$ (7,971,909)
Net loss attributable to noncontrolling interest		145,522	81,200	314,273	81,200
Net loss - as reported, attributable to PAVmed Inc.		(3,593,611)	(5,065,340)	(7,128,473)	(7,890,709)
Convertible Preferred Stock dividends Series B	[1]	(66,792)	(63,623)	(132,273)	(74,029)
Convertible Preferred Stock dividends Series A-1	[1]				(25,148)
Convertible Preferred Stock dividends Series A	[1]				(26,487)
Series A and Series A-1 Exchange Offer - March 15, 2018-deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock					(726,531)
Series A and Series A-1 Exchange Offer - March 15, 2018 - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock					199,241
Net loss attributable to PAVmed Inc. common stockholders		$ (3,660,403)	$ (5,128,963)	$ (7,260,746)	$ (8,543,663)
Weighted-average common shares outstanding basic and diluted	[2],[3]	27,605,881	19,289,874	27,343,912	17,924,632
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc		$ (0.13)	$ (0.26)	$ (0.26)	$ (0.44)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders		$ (0.13)	$ (0.27)	$ (0.27)	$ (0.48)
[1]	The convertible preferred stock dividends are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective periods presented, including: with respect to the prior year periods, the Series B Convertible Preferred Stock from March 16, 2018 to June 30, 2018, and each of the Series A-1 and Series A Convertible Preferred Stock from January 1, 2018 to March 15, 2018. See Note 12, Preferred Stock, for a further discussion of the dividends for each of the respective series of convertible preferred stock.
[2]	Basic weighted-average number of shares of common stock outstanding for the period excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. Notwithstanding, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
[3]	The Series B Convertible Preferred Stock has the right to receive common stock dividends. As such, the Series B Convertible Preferred Stock would potentially been considered participating securities under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and the holders are not contractually obligated to share in the losses

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities excluded from computation of diluted weighted shares outstanding	25,418,970	22,559,840
Stock Options and Restricted Stock Awards - PAVmed Inc. 2014 Equity Plan [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	5,803,529	3,082,032
Unit Purchase Options - "UPO-Z" /"UPO-W" - as to Shares of common stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53,000	53,000
Unit Purchase Options - "UPO-Z" - as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53,000
Unit Purchase Options - "UPO-W" - as to Shares Underlying Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		53,000
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	16,815,039	16,815,039
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	381,818	381,818
Series S Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,199,383	1,199,383
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,113,201	975,568